Download Files:
BKI-1369
$500 – $3,600
Products Details
Product Description
– BKI-1369 is a bumped kinase inhibitor (BKI). BKI-1369 increases human Ether-a-go-go-related gene (hERG)-inhibitory activity with an IC50 of 1.52 μM. BKI-1369 reduces the parasite burden and diseases severity in the gnotobiotic pig model. BKI-1369 has been well characterized for potency, stability, metabolism, toxicity, pharmacokinetics and is potent against C. parvum in infected mice and calves[1].
Web ID
– HY-121495
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C23H27N7O
References
– [1]Lee S, et al. Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by <i>Cryptosporidium hominis</i>. Antimicrob Agents Chemother. 2018 Jun 26;62(7).
CAS Number
– 1951431-22-3
Molecular Weight
– 417.51
Compound Purity
– 99.71
SMILES
– NC1=C2C(N(CC3CCN(C)CC3)N=C2C4=CC=C5N=C(OCC)C=CC5=C4)=NC=N1
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– DMSO : 50 mg/mL (ultrasonic)
Target
– Parasite
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
